Combined analysis of eGFR and albuminuria over 2 years has been shown to predict T2DM patients’ risk for major macrovascular outcomes.

Final results from a phase 3 study preceded FDA approval of oral semaglutide.

A secondary analysis of the LEADER trial to investigate the safety of liraglutide in patients with type 2 diabetes. 

Both patients and HCPs should be aware of early signs of kidney issues.

People with metabolically healthy obesity may not remain free of metabolic diseases in the long term.

Studies show a link between diabetic peripheral neuropathy and sarcopenia, which increases frailty and subsequent mortality.

Patients with diabetes are two times more likely to present with symptoms of depression; how does this affect diabetes outcomes?

While cardiovascular risk factors are used to predict risk for clinical outcomes and base therapies, it may be a fluctuation in such risk factor measurements that has the most impact.

Heart failure is a common macrovascular complication that may occur in patients with diabetes, but what gender is more prone to have continuous hospitalization for heart failure problems?

A recent study demonstrates the efficacy of a new, once daily oral option for patients with type 2 diabetes already on metformin.